Pfizer and Flynn Pharma: The end of the road for excessive pricing cases?

Following an increase of up to 2,600 per cent in the price of their anti-epilepsy drug, the UK Competition and Markets Authority fined Pfizer and Flynn Pharma nearly £90 million for unfair prices charged to the NHS. In its judgment, the Competition Appeal Tribunal has since set aside the authority’s fine. This briefing considers whether the judgment signals the end of excessive pricing cases.